10 Best Small-Cap Stocks to Buy Now

Page 9 of 9

1. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Analyst Upside: 41.51%

No. of Hedge Fund Holders: 39

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is a biotechnology company developing novel small-molecule drugs that target key enzymes involved in infectious and inflammatory diseases.

2024 was a year of development with strong financial progress for BioCryst Pharmaceuticals. For the full-year 2024, the company posted revenues of $450.7 million, a 36% year-over-year growth. The company’s GAAP operating loss was around $2.5 million in 2024, a notable improvement from a loss of $103.7 million in 2023. BioCryst’s revenue growth was primarily driven by ORLADEYO, the company’s lead product, which generated around $124.2 million in net revenue, reflecting a 36.6% increase from a year ago. On February 12, the company reported that Infarmed in Portugal has recommended ORLADEYO for the routine prevention of recurrent attacks of hereditary angioedema (HAE) in eligible patients. This development is set to add to ORLADEYO sales in 2025.

Based on strong performance in 2024, the company has raised its 2025 revenue guidance to $560 to $575 million. ORLADEYO’s revenue is expected to reach $535 to $550 million in 2025. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is aiming to achieve a 20% revenue CAGR over the next three years and targets $750 million in global revenue by 2027.

While we acknowledge the potential of BCRX to grow, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BCRX but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap.

Disclosure. None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and investors. Please subscribe to our daily free newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

Page 9 of 9